Latest Conference Articles

December 11th 2021, 10:41pm

ASH Annual Meeting and Exposition

The addition of subcutaneous daratumumab to standard-of-care bortezomib, cyclophosphamide, and dexamethasone (D-VCd) continued to elicit stronger hematologic and organ responses vs VCd alone in patients with newly diagnosed light chain amyloidosis.

December 11th 2021, 10:05pm

ASH Annual Meeting and Exposition

The addition of isatuximab to lenalidomide, bortezomib, and dexamethasone (RVd) demonstrated superior minimal residual disease rates vs RVd alone when used as induction treatment in patients with transplant-eligible newly diagnosed multiple myeloma.

December 11th 2021, 10:05pm

ASH Annual Meeting and Exposition

Tisagenlecleucel produced a high overall response rate and complete response rate in adult patients with relapsed/refractory follicular lymphoma who had received 2 or more prior lines of therapy, according to results from an extended follow-up analysis of patients with at least 12 months of follow-up of the phase 2 ELARA trial.

December 11th 2021, 9:45pm

ASH Annual Meeting and Exposition

Axicabtagene ciloleucel induced high response rates and improved survival in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma, according to updated data from the phase 2 ZUMA-5 trial.

December 11th 2021, 9:29pm

ASH Annual Meeting and Exposition

Daratumumab plus talquetamab demonstrated a tolerable safety profile and induced responses in more than 75% of patients with relapsed/refractory multiple myeloma across dose levels.

December 11th 2021, 8:50pm

ASH Annual Meeting and Exposition

Parsaclisib demonstrated early and long-lasting responses in patients with BTK-naïve, relapsed/refractory marginal zone lymphoma, according to findings from the phase 2 CITADEL-204 trial.

December 11th 2021, 8:35pm

ASH Annual Meeting and Exposition

The use of ibrutinib plus venetoclax in the first-line setting for patients with previously untreated chronic lymphocytic leukemia continues to provide deep, durable responses, according to updated results from the MRD cohort of the phase 2 CAPTIVATE trial.

December 11th 2021, 8:00pm

ASH Annual Meeting and Exposition

The combination of obinutuzumab and venetoclax (GVe), as well as GVe plus ibrutinib demonstrated superior rates of undetectable minimal residual disease compared with chemoimmunotherapy in fit patients with chronic lymphocytic leukemia, according to findings from the phase 3 GAIA (CLL13) trial.

December 11th 2021, 7:51pm

ASH Annual Meeting and Exposition

Frontline fixed-duration treatment with ibrutinib plus venetoclax led to deeper and prolonged rates of undetectable minimal residual disease in the bone marrow and peripheral blood, leading to fewer relapses in the first year post-treatment vs chlorambucil plus obinutuzumab in elderly and unfit patients with chronic lymphocytic leukemia.

December 11th 2021, 7:44pm

ASH Annual Meeting and Exposition

The minimal residual disease–guided combination of ibrutinib plus venetoclax was found to be a feasible treatment regimen for patients with relapsed/refractory chronic lymphocytic leukemia.

December 11th 2021, 7:40pm

ASH Annual Meeting and Exposition

Orca-T significantly improved graft-vs-host disease–free relapse-free survival and time to engraftment, significantly reduced acute and chronic GVHD, and showed a trend toward improved overall survival vs standard of care in patients with serious hematologic malignancies

December 11th 2021, 7:10pm

ASH Annual Meeting and Exposition

Daratumumab, lenalidomide, and dexamethasone demonstrated an overall survival advantage in the first-line setting compared with the same agents in the second-line setting in patients with transplant-ineligible multiple myeloma.

December 11th 2021, 6:32pm

ASH Annual Meeting and Exposition

Fixed-duration treatment with the bispecific antibody mosunetuzumab induced deep and durable responses with favorable tolerability in heavily pretreated patients with relapsed or refractory follicular lymphoma, meeting the primary end point of the ongoing phase 1/2b GO29781 trial.

December 11th 2021, 6:22pm

ASH Annual Meeting and Exposition

The combination of daratumumab plus ixazomib, without dexamethasone, was found to have a favorable safety profile in very elderly frail patients with relapsed or refractory multiple myeloma and high cytogenetic risk.

December 11th 2021, 6:16pm

ASH Annual Meeting and Exposition

Lisocabtagene maraleucel demonstrated statistically and clinically meaningful improvement in event-free survival compared with the standard of care as a second-line therapy in patients with relapsed or refractory large B-cell lymphoma.

December 11th 2021, 5:56pm

ASH Annual Meeting and Exposition

The combination of ixazomib, daratumumab, and low-dose dexamethasone elicited an objective response rate of 71% in non-transplant eligible, intermediate-fit patients with newly diagnosed multiple myeloma.

December 10th 2021, 11:03pm

San Antonio Breast Cancer Symposium

Neratinib (Nerlynx) induced positive overall response rates in patients with heavily pretreated hormone receptor–positive/HER2-negative, HER2-mutant metastatic breast cancer when combined with fulvestrant and trastuzumab, and also in patients with metastatic HER2-mutant triple-negative breast cancer when combined with trastuzumab.

December 10th 2021, 9:09pm

San Antonio Breast Cancer Symposium

Aditya Bardia, MD, MPH, discusses the efficacy results of the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative metastatic breast cancer.

December 10th 2021, 8:53pm

San Antonio Breast Cancer Symposium

Certain adverse effects associated with olaparib were minimal and resolved with appropriate management in patients with germline BRCA1/2 mutations in patients with high-risk, HER2-negative, early-stage breast cancer.

December 10th 2021, 8:36pm

San Antonio Breast Cancer Symposium

Pathologic complete response and event-free survival was not found to be significantly affected by race among patients with high-risk breast cancer who received neoadjuvant chemotherapy; however, disparities were observed among patients who did not achieve a pCR.